A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease

Código QR

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease

Joseph Tauber,1 Barry A Schechter,2 Jason Bacharach,3 Melissa M Toyos,4 Robert Smyth-Medina,5 Sidney L Weiss,6 Jodi I Luchs7 1Tauber Eye Center, Kansas City, MO, USA; 2Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 3North Bay Eye Associates, Petaluma, CA, USA; 4Toyos Clinic, Nashville...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Dry eye disease cyclosporine inflammation Schirmer test Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d3081699ac5545039b3bca544fc4d571
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
por: Tauber J, et al.
Publicado: (2019)

A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
por: Tauber J, et al.
Publicado: (2018)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard J, et al.
Publicado: (2021)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
por: Karpecki PM, et al.
Publicado: (2019)

Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients
por: Miyake H, et al.
Publicado: (2016)

Evaluation of Tear Film Urea Level as a Diagnostic Marker of Dry Eye Disease: A Pilot Study
por: Gurunadh Satyanarayana Velamakanni, et al.
Publicado: (2021)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

Development of a highly sensitive and reliable enzyme-linked immunosorbent assay for MUC5AC in human tears extracted from Schirmer strips
por: Miyake H, et al.
Publicado: (2018)

Impression cytology implicates cell autophagy in aqueous deficiency dry eye
por: Lin T, et al.
Publicado: (2017)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears
por: Epitropoulos AT, et al.
Publicado: (2020)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye
por: Sambursky R
Publicado: (2016)

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Making the diagnosis of Sjögren’s syndrome in patients with dry eye
por: Beckman KA, et al.
Publicado: (2015)

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial
por: Silverstein S, et al.
Publicado: (2020)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman LM, et al.
Publicado: (2020)

Cyclosporine A micellar delivery system for dry eyes
por: Kang H, et al.
Publicado: (2016)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian JA, et al.
Publicado: (2021)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White DE, et al.
Publicado: (2019)

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
por: Shen Lee B, et al.
Publicado: (2020)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella P, et al.
Publicado: (2018)

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
por: Jerkins G, et al.
Publicado: (2020)

Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
por: Yeu E, et al.
Publicado: (2020)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

Effectiveness of Subconjunctival Cyclosporine in Treatment of Acute Allergic Conjunctivitis in a Rat-Model
por: Awara A, et al.
Publicado: (2020)

Objective assessment of optical quality in dry eye disease using a double-pass imaging system
por: Gouvea L, et al.
Publicado: (2019)

Impact of Thermal Pulsation Treatment on Astigmatism Management and Outcomes in Meibomian Gland Dysfunction Patients Undergoing Cataract Surgery
por: Matossian C
Publicado: (2020)

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
por: Taylor M, et al.
Publicado: (2019)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin MR, et al.
Publicado: (2017)

Adaptación cultural y validación del cuestionario Ocular Surface Disease Index en una población chilena
por: Traipe,Leonidas, et al.
Publicado: (2020)

Comparing SPEED and OSDI Questionnaires in a Non-Clinical Sample
por: Hashmani N, et al.
Publicado: (2021)

The Efficacy and Safety of Trehalose in Primary Trabeculectomy with Mitomycin C: A Report of Early Findings
por: Sen E, et al.
Publicado: (2021)

Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
por: Jariyakosol S, et al.
Publicado: (2021)

Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
por: Yeu E, et al.
Publicado: (2019)

A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction
por: Oleñik A, et al.
Publicado: (2013)

Trends in Dry Eye Disease Management Worldwide
por: Hantera MM
Publicado: (2021)

Patient-reported severity of dry eye and quality of life in diabetes
por: Yazdani-Ibn-Taz MK, et al.
Publicado: (2019)